Fig. 3From: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trialPosterior density of the hazard ratio of death within 60 deaths in DXM20 over DXMSoc group, according to subsets. Subsets were defined by age (< , > 70, Fig. 2a), by time since symptoms onset (< , > 7 days, Fig. 2b) and by remdesivir use or not (Fig. 2c)Back to article page